Dr. Ram Yogendra
speaker
332 appearances
3 recordings
1 series
first heard May 2025
last heard 13 Aug
Dr. Ram Yogendra’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Aug 2026 with 2.
Appearances
Yeah, I've seen that, you know, in fact, we have in our Vax paper, there is a potential, you know, a signal there with some of the immune markers, um, that might be that, that are sort of tumor checkpoints, um, that, that regulate the checkpoints and tumor, um, in angiogenesis. So. You know, I think there's a lot more to uncover with that spike protein and what was injected in people.
And we just need to have those uncomfortable conversations. The other thing, too, I just want to mention, Drew, that we can't study long COVID without acknowledging the vaccine, injured patients. Yeah. Congress has given $1.6 billion to the NIH, and no one knows where this money has gone. Stat News and Washington Post have been writing articles about this.
The congressmen that we talked to are just frustrated. They said, well, where is this money gone? And if you look at the research that's going in long COVID – and I hope Dr. Bhattacharya and Bobby Kennedy look into this – Hey, how are we spending this money on long COVID? Because they're just going around in circles, like no one is acknowledging the vaccine injured.
And you have to include them if you're going to study long COVID, otherwise we're wasting US taxpayer dollars. And quite frankly, you're not seeing anything meaningful coming out of that $1.6 billion that have been allocated by Congress.
I post on X, Dr. Yostradamus on X. I post all my papers there. And in the next couple of days, we should have the vaccine paper on there. And then we post updates on all the work that we're doing with our research with long COVID and the vaccine studies. And hopefully in the And next couple of weeks, we'll get a green light from the FDA on a vaccine clinical trial.
So we try to get some help for these patients out there.
Absolutely. Clinical trials. Let's, you know, we got all this money rather than funding. I don't know what, what they're funding this money for. You know, one of the, you know, one of the studies they were looking at was kimchi, uh, One of the studies that was allocated from the NIH RECOVER trial to study long COVID was Kim Chi. I remember looking at this going, are you kidding me?
So we need some oversight and some deep dive into how this money has been spent. And just like you said, Drew, there's some really interesting stuff there, colchicine, the anticoagulants, and let's get some clinical trials and some data out there that we can make some meaningful impact in people's lives.
Drew, you and Susan have been, I mean, so instrumental and supportive, especially times when I would text you and say, Drew, you know, F this, I can't do this. And you just, you and Susan were awesome in, you know, helping me push through. You were on dose of Dr. Drew.
He just got part of it. I think a lot of us did. Yeah.
But a lot of us did, Drew. We believe in our institutions, and then now we're questioning everything, not only from COVID, but what we've been taught in med school in the last several decades.
I will. Thanks, Drew. Thanks, Susan. Appreciate the support.
Showing 321–332 of 332 · page 17 of 17
← Previous